跳至主要内容
临床试验/NCT00953212
NCT00953212已完成3 期

A Randomized Controlled Trial to Compare Prophylaxis With Oral Ascorbic Acid, Oral Amiodarone or Both in Combination With Beta Blockers to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

MaineHealth1 个研究点 分布在 1 个国家目标入组 304 人开始时间: 2009年8月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
MaineHealth
入组人数
304
试验地点
1
主要终点
Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery

研究概览

简要总结

Atrial Fibrillation (AF) is a common postoperative complication of cardiac surgery, occuring in approximately 25-30% of coronary artery bypass graft (CABG) patients and 35-40% of heart valve repair/replacement patients. Efforts to decrease the high rates of AF have not made great inroads to the problem. The current standard of care is the use of preoperative and postoperative beta blockers. We propose to compare the use of prophylactic oral ascorbic acid with and without prophylactic oral amiodarone, in combination with oral beta blockers, for the prevention of atrial fibrillation after open heart surgery. The hypothesis is that either drug, or a combination of the two drugs, will be superior and safe when compared to beta blockers alone.

详细描述

Atrial fibrillation is a common complication of cardiac surgery which is associated with increased morbidity, length of stay and cost. Efforts to mitigate this problem with beta blockers and amiodarone have been met with limited success. Observational data suggests that prophylactic amiodarone has been helpful in decreasing the incidence of AF as well as increasing its ease of management. The opportunity to use ascorbic acid for AF prophylaxis is attractive because of its low side effect profile, wide acceptance and low cost.

We have designed a prospective, randomized, controlled trial using a 2 X 2 factorial design to determine whether prophylactic ascorbic acid alone, ascorbic acid with amiodarone, or amiodarone alone, when given along with beta blockers will decrease the incidence of postoperative AF in adult cardiac surgery in all comers as compared with beta blockers alone.

Patients will be randomized into four groups, A, B, C, and D. All groups will receive beta blockers, Group A will receive beta blockers, ascorbic acid, and amiodarone, Group B will receive ascorbic acid and Beta blockers, Group C will receive amiodarone and beta blockers and Group D will receive only beta blockers.

Success of randomization will be assessed by comparing treatment groups with respect to baseline characteristics, using t-tests or their nonparametric equivalent (as appropriate) for continuous variables and chisquare tests or Fisher's exact tests for categorical variables. The primary hypotheses of the effects of ascorbic acid and amiodarone on incidence of atrial fibrillation will be tested using chisquare tests for differences in proportions. No adjustment will be made for multiple comparisons since both hypotheses are pre-specified. We will use exploratory analyses including stratification to assess for the possibility of effect modification between ascorbic acid and amiodarone. If an interaction is suggested by these analyses, we will use logistic regression with a cross-product term as a formal statistical test for interaction.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Factorial
主要目的
Prevention
盲法
Double (Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • adults (18 years of age or older)
  • all comers for elective or urgent open heart surgery ( CABG, Valve repair or replacement, Combined CABG/Valves, CABG/other, Other)

排除标准

  • patients who refuse to participate
  • patients with a history of atrial fibrillation or atrial flutter
  • pediatric patients (under 18 years of age)
  • Emergency surgery
  • patients with contraindications to study medications
  • patients with untreated thyroid disease, hepatic failure, pregnancy

研究组 & 干预措施

Group D

Active Comparator

Beta Blockers alone

干预措施: beta blockers (Drug)

Group A

Active Comparator

Beta Blockers, Ascorbic Acid and Amiodarone

干预措施: beta blockers (Drug)

Group A

Active Comparator

Beta Blockers, Ascorbic Acid and Amiodarone

干预措施: amiodarone (Drug)

Group A

Active Comparator

Beta Blockers, Ascorbic Acid and Amiodarone

干预措施: ascorbic acid (Drug)

Group B

Active Comparator

Beta Blockers and Ascorbic Acid

干预措施: beta blockers (Drug)

Group B

Active Comparator

Beta Blockers and Ascorbic Acid

干预措施: ascorbic acid (Drug)

Group C

Active Comparator

Beta Blockers and Amiodarone

干预措施: beta blockers (Drug)

Group C

Active Comparator

Beta Blockers and Amiodarone

干预措施: amiodarone (Drug)

结局指标

主要结局

Occurrence of Post-operative Atrial Fibrillation Requiring Treatment After Open Heart Surgery

时间窗: 5 postoperative days

Atrial fibrillation is a common complication of cardiac surgery which is associated with increased morbidity, length of stay and cost. The opportunity to use ascorbic acid for AF prophylaxis is attractive because of its low side effect profile, wide acceptance and low cost. This prospective, randomized trial used a 2 X 2 factorial design to determine whether prophylactic ascorbic acid alone, ascorbic acid with amiodarone, or amiodarone alone, when given along with beta blockers would decrease the incidence of postoperative AF in adult cardiac surgery when compared with beta blockers alone, all combinations failed to show any difference between the four groups. While there have been trials that have shown the addition of amiodarone to beta-blockers to be more effective, this analysis does not support that conclusion.

次要结局

  • Number of Participants With Postoperative Vasoplegia(30 days)
  • Number of Participants With Mortality(30 days)
  • Hospital Length of Stay(30 days)
  • ICU Length of Stay(30 days)
  • Number of Participants With Bradycardia Necessitating Permanent Pacemaker Placement(30 days)
  • Number of Participants With Stroke(30 days)
  • Number of Participants With Low Output Heart Failure(30 days)
  • Number of Participants With Acute Kidney Injury(30 days)
  • Number of Participants With Readmission to Hospital for Treatment of Atrial Fibrillation(30 days)
  • Number of Participants With Respiratory Failure Requiring Reintubation(30 days)
  • Number of Participants With Readmission to ICU for Treatment of Atrial Fibrillation(30 days)

研究者

发起方
MaineHealth
申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter C. Donovan

Staff Physician Assistant, Cardiothoracic Surgery

MaineHealth

研究点 (1)

Loading locations...

相似试验